Summit Therapeutics Inc.
ivonescimab
non-small cell lung cancer (NSCLC)
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews ivonescimab for non-small cell lung cancer (NSCLC) around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“the purpose of this interim analysis was to provide a potential opportunity to speak with the regulatory authorities, including the US Food & Drug Administration, earlier than the timing of the preplanned final PFS analysis in the second ha”